MyoKardia

MyoKardia is a clinical-stage biopharmaceutical company that engages in discovering, developing, and commercializing targeted therapies for the treatment of rare cardiovascular diseases. The company's focus is on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It utilizes its medicine platform to generate an initial pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy-hypertrophic cardiomyopathy and dilated cardiomyopathy.  The company was founded in 2012 and is headquartered in Brisbane, California.

BRISBANE, Calif., May  12, 2020  (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of $105.00 per share, before underwriting discounts. In addition, the underwriters have a 30-day option to purchase up to an additional 787,500 shares of common stock on the same terms and conditions. The offering is expected to close on or about May 15, 2020, subject to the satisfaction of customary closing conditions. 

MyoKardia Announces Pricing of Public Offering of Common Stock

MyoKardia (NASDAQ: MYOK) shares are trading higher on Tuesday. On Monday, the company announced the primary and secondary endpoints for its Phase 3 EXPLORER clinical trials of Mavacamten were met.

Why MyoKardia's Stock Is Trading Higher Today

BRISBANE, Calif., May  11, 2020  (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, today announced that it has commenced a proposed underwritten public offering to sell $450.0 million in shares of its common stock. MyoKardia expects to grant the underwriters a 30-day option to purchase up to $67.5 million in additional shares of common stock at the public offering price, less the underwriting discount. All shares of common stock will be offered by MyoKardia. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

MyoKardia Announces Proposed Public Offering of Common Stock

MyoKardia Inc. (NASDAQ: MYOK) shares made an incredible gain on Monday after the company announced positive results from its late-stage pivotal clinical trial of mavacamten in patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM).

Why MyoKardia’s Late-Stage Hypertophric Cardiomyopathy Study Is a Big Hit

Investors need to pay close attention to MyoKardia (MYOK) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in MyoKardia (MYOK) Stock?

The company's experimental heart drug hit the mark in a pivotal study.

Why MyoKardia Stock Is on Fire Today

Myokardia shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Stock Upgrades: Myokardia Shows Rising Relative Strength

Are Options Traders Betting on a Big Move in MyoKardia (MYOK) Stock?

Axsome Therapeutics

Horizon Pharma

These drug developers just released new clinical trial results.

Should You Buy These 3 Biotechs Now?

MAVERICK-HCM Phase 2 Clinical Trial Results Consistent with Tolerability Observations from Prior Studies of Mavacamten

MyoKardia Announces Mavacamten Treatment Well Tolerated and Significantly Reduced Biomarkers of Cardiac Injury and Wall Stress in Non-Obstructive Hypertrophic Cardiomyopathy Patients

Reaffirms Second Quarter 2020 Expected Timing for Topline Data from Phase 3 EXPLORER-HCM Clinical Trial of Mavacamten and Phase 2a Danicamtiv Study Reaffirms Second Quarter 2020 Expected Timing for Topline Data from Phase 3 EXPLORER-HCM Clinical Trial of Mavacamten and Phase 2a Danicamtiv Study

MyoKardia Provides Clinical Trial Update in the Context of the COVID-19 Pandemic

Virtual Analyst and Investor Event to Review Data Planned for 4:30 p.m. EDT on March 30 Virtual Analyst and Investor Event to Review Data Planned for 4:30 p.m. EDT on March 30

Data from MAVERICK-HCM Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy Selected for Virtual Late-Breaker Presentation at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology

MyoKardia, Inc. (MYOK) CEO Tassos Gianakakos on Q4 2019 Results - Earnings Call Transcript

Implied Volatility Surging for MyoKardia (MYOK) Stock Options

Ally Financial

CoStar Group

Everbridge

National Vision Hlds

II-VI Incorporated

Ingersoll-Rand

Lowe's

MarketAxess Holdings

Vail Resorts

Navigator Hlds

Vulcan Materials

Vertex Pharmaceuticals

Wayfair

Yext

Top stock picks for 2020, according to the best portfolio managers.

20 Great Stock Ideas For 2020, From The Best Fund Managers

MyoKardia - Don't Give Yourself Heartburn

Shares of Myokardia toppled and sacrificed a cup base Monday as investors questioned the safety of the biotech company's treatment for nonobstructive hypertrophic cardiomyopathy.
The post Why This Biotech Stock Sacrificed Its Cup Base And Hit A Sell Signal appeared first on Investor's Business Daily.

Why This Biotech Stock Sacrificed Its Cup Base And Hit A Sell Signal

Achieved Primary Study Objective of Safety and Tolerability in Patients with Non-obstructive HCM

MyoKardia Announces Positive Topline Data from its Phase 2 MAVERICK-HCM  Clinical Trial of Mavacamten

Interim Data Demonstrated Favorable Safety and Activity Profile in Phase 2a Multiple-Ascending Dose Study

MyoKardia Announces Positive MYK-491 Data; Advancing Program into Targeted Genetic Dilated Cardiomyopathy Population

SOUTH SAN FRANCISCO, Calif., Sept.  26, 2019  (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Taylor Harris, Chief Financial Officer, will participate in a fireside chat at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019, at 4:10 p.m. ET in New York, NY.

MyoKardia to Present at 2019 Cantor Global Healthcare Conference

Planned Study Will Assess Effect of Mavacamten on the Need for SRT Among HCM Patients Referred for Invasive Procedures Planned Study Will Assess Effect of Mavacamten on the Need for SRT Among HCM Patients Referred for Invasive Procedures

MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Patients

Durability of Mavacamten's Safety and Efficacy Profile Demonstrated through Nine Months in this Study of Patients with Symptomatic, Obstructive HCM

MyoKardia Presents 36-week Data from PIONEER-OLE Study of Mavacamten at the European Society of Cardiology Congress 2019

SOUTH SAN FRANCISCO, Calif., Aug.  28, 2019  (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced its participation in the following upcoming investor conferences:

MyoKardia to Participate in September Investor Conferences

MyoKardia Inc (NASDAQ: MYOK), a thinly traded mid-cap biotech, is on the radar of investors ahead of the company's scheduled presentation at the European Society of Cardiology Congress Aug.

Biotech Stock On The Radar: MyoKardia Bets On Precision Medicine For Heart Health

SOUTH SAN FRANCISCO, Calif., Aug.  26, 2019  (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the presentation of three abstracts at the upcoming European Society of Cardiology (ESC) Congress taking place August 31 – September 4, 2019 in Paris, France. Among the highlights of the data being presented are 36-week safety and efficacy data from the PIONEER open-label extension (PIONEER-OLE) study.

News for MyoKardia Stock (MYOK)